A blood test, combined with an ultrathin material derived from graphite, could significantly advance efforts to detect Alzheimer’s disease at its very earliest stage, even before symptoms appear.

Alzheimer’s disease is the most common form of dementia. For millions of Europeans—and the health services that care for them—it is a ticking time bomb, with still no cure. But EU researchers are developing a simple tool to enable much earlier detection, potentially decades before symptoms appear.

Early detection matters because treatment is most effective when started as soon as possible. This gives people a better chance to slow the progression of the disease and plan for the future. Today, around 7 million people in Europe live with Alzheimer’s, a number expected to double by 2030, according to the European Brain Council.